Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 16, 2020
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
Journal: Gynecologic oncology
Published: March 12, 2020
Conversion of MyoD to a neurogenic factor: binding site specificity determines lineage.
Journal: Cell reports
Published: September 18, 2014
Discriminative motif analysis of high-throughput dataset.
Journal: Bioinformatics (Oxford, England)
Published: October 29, 2013
Skeletal muscle programming and re-programming.
Journal: Current opinion in genetics & development
Published: March 18, 2013
Genome-wide binding of the basic helix-loop-helix myogenic inhibitor musculin has substantial overlap with MyoD: implications for buffering activity.
Journal: Skeletal muscle
Published: March 17, 2013
Comparison of genome-wide binding of MyoD in normal human myogenic cells and rhabdomyosarcomas identifies regional and local suppression of promyogenic transcription factors.
Journal: Molecular and cellular biology
Published: December 12, 2012
Comparison of endogenous and overexpressed MyoD shows enhanced binding of physiologically bound sites.
Journal: Skeletal muscle
Published: October 02, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026